HTEC Index 3rd Quarter 2026 Commentary

As of September 30, 2026

The ROBO Global Healthcare Technology and Innovation Index (HTEC) ended the third quarter with a return of 18.64%, building on the momentum established in the second quarter. Gains were broad, with Genomics and Data Analytics leading the advance as investors continued to focus on molecular diagnostics, clinical data integration, and AI-enabled healthcare technologies.

Seven of the index's nine subsectors generated positive returns during the period, reflecting participation across several areas of healthcare innovation.

Top Performing Subsectors

Genomics led the index for the second consecutive quarter with a 57.37% return, following 60.94% in Q2. Data Analytics was the second strongest subsector with a 47.62% gain, followed by Process Automation at 26.31%, Precision Medicine at 16.32%, and Diagnostics at 14.34%, rounding out the subsectors with double-digit returns.

Moderna (Precision Medicine) delivered a standout return of 174.98%. Its investigational individualized mRNA cancer therapy, intismeran autogene, is being developed with Merck and studied in combination with Merck's Keytruda for melanoma and other cancers. The program represents an important part of Moderna's effort to expand beyond respiratory vaccines, although its ultimate commercial impact remains dependent on clinical outcomes and regulatory review.

The program also illustrates the role of genomic analysis in personalized cancer treatment. Personalis provided sequencing for the clinical development program, while Tempus AI's agreement with Moderna concerns a prospective commercial role in genomic sequencing. The agreement addresses potential commercialization rather than the trial itself. More broadly, personalized therapies create demand for sequencing, analytics, and manufacturing capabilities across the healthcare technology ecosystem.

Within Genomics, CareDx Inc returned 128.07%, while GRAIL Inc gained 105.24%. Twist Bioscience advanced 87.83%, following 116.50% in Q2. Twist's work as one of the independent evaluators in Anthropic's research highlights the intersection of synthetic biology and AI. Illumina Inc (+55.65%), Natera Inc (+52.26%), and Adaptive Biotechnologies Corp (+34.73%) further reinforced subsector breadth. Together, these businesses illustrate the range of genomic tools supporting diagnostics, research, and clinical decision-making.

In Data Analytics, Veeva Systems Inc advanced 60.84%, while Tempus AI Inc continued its momentum with a 41.38% gain. Their platforms address demand for life sciences software and the integration of clinical and molecular data.

In Process Automation, new index constituent Insilico Medicine advanced 51.60%. IQVIA Holdings Inc (+39.14%), Tecan Group AG (+39.96%), and Thermo Fisher Scientific Inc (+34.71%) also posted strong gains, demonstrating the breadth of the subsector beyond AI-driven drug discovery.

In Medical Instruments, Conmed Corporation returned 41.25%, while Becton, Dickinson and Company gained 18.77% and Glaukos advanced 17.45%.

Subsector Laggards

Robotics recorded the weakest subsector return during the quarter, declining 8.34%. Regenerative Medicine was also in the red, dropping 4.58%. Capital expenditure discipline and sales cycles for high-cost equipment remain important considerations for investors in capital-intensive healthcare technologies.

Within Robotics, Omnicell Inc fell 17.99%, while Novanta Inc declined 12.36% and Stryker Corporation dropped 12.33%.

In Medical Instruments, Align Technology Inc declined 12.48%. Demand for discretionary orthodontic procedures remains sensitive to consumer spending conditions.

Long Term Outlook

The structural drivers underpinning healthcare technology innovation remain strong. Aging populations, chronic disease burdens, clinical labor shortages, and rising healthcare expenditures continue to create demand for platforms that improve care and efficiency.

Short-term capital deployment dynamics may create uneven performance across capital-intensive subsectors such as Robotics and Medical Instruments. Over time, the opportunity for HTEC companies will depend on their ability to translate innovation into measurable clinical utility, operational productivity, and sustained commercial adoption.

About VettaFi

VettaFi is a differentiated index provider, helping asset managers across the globe build and grow their product suites. With an industry-leading index platform, VettaFi partners with issuers to develop innovative investment solutions and bring them to market. VettaFi's portfolio of investor-oriented media publications and events connects clients' products with investors. This robust ecosystem enables asset managers to effectively reach their target audience, whether digitally or in-person.

Significant investments and the backing of TMX Group have further strengthened our ability to help our partners by expanding our capability set and geographic reach.

Our combined strength and entrepreneurial spirit empowers us to deliver the specialized insights and services that enable asset managers and investors to achieve growth and success.

VettaFi owns and administers the ROBO Global Index Series. For more information, please visit: www.vettafi.com.

vettafi.com | 225 Liberty Street, 23rd Floor, New York, NY 10281

VettaFi Disclaimer

This Document Is Impersonal and Not a Solicitation. ROBO Global, LLC is a wholly owned subsidiary of VettaFi LLC. VettaFi LLC, collectively with its affiliates and subsidiaries, is referred to herein as ("VettaFi"). This document does not constitute an offering of any security, product, or service. All information provided by VettaFi in this document is impersonal and not customized to the specific needs of any entity, person, or group of persons.

About the Index. The ROBO Global® Healthcare Technology and Innovation Index Series' objective is to provide investors with comprehensive, transparent and diversified benchmarks representing the global value chain of disruptive and emerging technologies in the healthcare sector. The index series benchmark companies that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. The Index and its trademarked name are the exclusive property of VettaFi.

No Advisory Relationship. VettaFi is not a fiduciary or an investment advisor, and VettaFi makes no representation regarding the advisability of investing in any investment fund or other vehicle. This document should not be construed to provide advice of any kind, including, but not limited to, investment, tax or legal.

You Must Make Your Own Investment Decision. It is not possible to invest directly in an index. Exposure to an asset class represented by an index is available through investable instruments based on that index. You should not make a decision to invest in any investment fund or other vehicle based on the statements set forth in this document. You should only make an investment in an investment fund or other vehicle after carefully evaluating the risks associated with such an investment in the investment fund, as detailed in the offering memorandum or similar document prepared by or on behalf of the issuer. This document does not contain, and does not purport to contain, the level of detail necessary to give sufficient basis to an investment decision. VettaFi does not sponsor, endorse, sell, promote, or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide an investment return based on the performance of any index.

No Warranties; Limitation of Liability. While VettaFi believes that the information contained in this document (collectively, the "Content") is reliable, VettaFi does not guarantee the accuracy, completeness, timeliness, or availability of the Content in whole or in part. VettaFi is not responsible for any errors or omissions, regardless of the cause, in the Content which may change without notice. VettaFi makes no warranties, express or implied, as to results to be obtained from use of the Content, and VettaFi expressly disclaims all warranties of suitability with respect thereto. VettaFi shall not be liable for any claims or losses of any nature in connection with the use of the Content, including but not limited to, lost profits or punitive or consequential damages, even if VettaFi has been advised of the possibility of same.

Research May Not Be Current. This document has been prepared solely for informational purposes based on information generally available to the public from sources believed to be reliable. VettaFi does not assume any obligation to update the Content following publication in any form or format.